Burnet Institute Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2015
NCT02363517
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Burnet Institute | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | Nadine Barnes

Active Ingredients

Drugs in Phase 4 Trials (3)

ivermectin (stromectol) (1 trial)

sofosbuvir (sovaldi) (3 trials)

velpatasvir (Epclusa) (2 trials)

Drugs in Phase 3 Trials (1)

ledipasvir (Harvoni) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis C (Phase 3)

Substance Abuse, Intravenous (Phase 3)

Substance-Related Disorders (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 4